The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics

European Respiratory Journal

Volumn 18, Issue 2, 2001, Pages 254-261

  Soler M ^a   Matz, J ^a   Townley, R ^a   Buhl, R ^a   O'Brien, J ^a   Fox, H ^a   Thirlwell, J ^a   Gupta, N ^a   Della Cioppa, G ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

Airway inflammation; Allergic asthma; Anti allergic drugs; Anti immunoglobulin E antibody; Immunoglobulin E; Omalizumab

Indexed keywords

BECLOMETASONE DIPROPIONATE; CORTICOSTEROID; IMMUNOGLOBULIN E ANTIBODY; OMALIZUMAB; PROTEIN; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ALLERGIC ASTHMA; ARTICLE; BODY WEIGHT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE CONTROL; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARESTHESIA; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; STEROID THERAPY; SYMPTOM; URTICARIA;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; ANTI-ASTHMATIC AGENTS; ANTIBODIES, MONOCLONAL; ASTHMA; BECLOMETHASONE; CHILD; DOUBLE-BLIND METHOD; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; IMMUNOGLOBULIN E; MALE; MIDDLE AGED; PEAK EXPIRATORY FLOW RATE; RECURRENCE; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 0034881877     PISSN: 09031936     EISSN: None     Source Type: Journal    
DOI: 10.1183/09031936.01.00092101     Document Type: Article

References (31)

1. British guidelines on asthma management: 1995 review and position statement
2. Current issues for establishing inhaled corticosteroids as the antiinflammatory agents of choice in asthma
3. Difficult asthma
4. Proceedings of the ATS workshop on refractory asthma. Current understanding, recommendations and unanswered questions
5. Allergic inflammation in upper and lower airways
6. Sorting out the cytokines of asthma: Commentary
7. Role of IgE in the development of allergic airway inflammation and airway hyperresponsiveness-a murine model
8. Immunologic basis of antigen-induced airway hyperresponsiveness
9. The diverse potential effector and immunoregulatory roles of mast cells in allergic disease
10. Association of asthma with serum IgE and skin-test reactivity to allergens
11. Relation between airway responsiveness and serum IgE in children with asthma and in apparently normal children
12. Relationship between serum IgE and airway responsiveness in adults with asthma
13. Total serum IgE and its association with asthma symptoms and allergic sensitization among children
14. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects
15. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic response
16. Treatment of allergic asthma with monoclonal anti-IgE antibody
17. Use of an anti-IgE humanised monoclonal antibody in ragweed-induced allergic rhinitis
18. Relationship between the clinical efficacy of rhuMAb-E25 (E25) and serum free IgE in seasonal allergic rhinitis
19. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis
20. Humanization of an antibody directed against IgE
21. The binding site on human immunoglobulin E for its high affinity receptor
22. Anti-IgE monoclonal antibodies that inhibit allergen-specific histamine release
23. IgE inhibition as a therapy for allergic disease
24. Central role of immunoglobulin (Ig) E in the induction of lung eosinophil infiltration and T helper 2 cell cytokine production: Inhibition by a non-anaphylactogenic anti-IgE antibody
25. Standard for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma
26. The costs of asthma
27. Effect of inhaled formoterol and budesonide on exacerbations of asthma
28. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA)
29. A research method to induce and examine a mild exacerbation of asthma by withdrawal of inhaled corticosteroid
30. Risk factors and costs associated with an asthma attack